NASDAQ
Dermata Therapeutics, Inc. - Warrant (DRMAW)
♥ 694 Thanks from members
Dermata Therapeutics faces severe dilution and going concern risks despite a recent $3.4 million private placement, ongoing direct-to-consumer Tome skincare pivot, and warrant restructuring.
No chart available for this instrument.